Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medical Device Innovation Consortium Advances Regulatory Science Projects

This article was originally published in The Gray Sheet

Executive Summary

At the Regulatory Affairs Professionals Society annual meeting last week, William Hawkins, chairman of the Medical Device Innovation Consortium, said the group is making progress in its first project on computer modeling and simulation, as well as future projects on clinical trial reform, and benefit-risk guidance and patient-centeredness.

You may also be interested in...



Replacing Test Subjects With Computer Models Will Take Cooperation

More collaboration between device companies and with FDA will be needed to employ sophisticated "virtual patient" computer models to reduce the number of patients needed in clinical trials, says Medtronic statistician Tarek Haddad.

Device Innovation Consortium Plans To Finish Patient-Centered Project This Year

The public-private partnership created to advance medical device regulatory science is starting 2014 with a renewed focus on its three projects and plans to possibly add a fourth to the mix.

FDA Expects Guidance On Validating Device Development Tools To Speed Approvals

A new FDA draft guidance establishes a voluntary process to validate publicly available device development tools so companies can routinely apply them to facilitate their path to market.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032477

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel